Embleema brings new cures sooner for patients with no available treatments by operating a health data & analytics platform that expedites evidence generation and regulatory reviews of new treatments in personalized medicine. Our platform is used by the FDA for its regulatory evaluation of health products involving genomic datasets and when life sciences use our platform, they align their bioinformatics submission with the FDA requirements and obtain regulatory approvals sooner. The FDA also uses our platform to power ARGOS, the regulatory-grade knowledge base of reference sequences of SARS-CoV-2 strains and other microbial pathogens.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):